These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Newhouse PA; Potter A; Levin ED Drugs Aging; 1997 Sep; 11(3):206-28. PubMed ID: 9303280 [TBL] [Abstract][Full Text] [Related]
5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713 [TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Maelicke A Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():11-8. PubMed ID: 10971047 [TBL] [Abstract][Full Text] [Related]
8. Cholinergic therapies for Alzheimer's disease: progress and prospects. Palmer AM Curr Opin Investig Drugs; 2003 Jul; 4(7):820-5. PubMed ID: 14619403 [TBL] [Abstract][Full Text] [Related]
9. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Volkow ND; Ding YS; Fowler JS; Gatley SJ Biol Psychiatry; 2001 Feb; 49(3):211-20. PubMed ID: 11230872 [TBL] [Abstract][Full Text] [Related]
10. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Lemière J; Van Gool D; Dom R Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352 [TBL] [Abstract][Full Text] [Related]
12. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Wallace TL; Porter RH Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954 [TBL] [Abstract][Full Text] [Related]
13. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related]
14. Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. Newhouse PA; Kelton M Pharm Acta Helv; 2000 Mar; 74(2-3):91-101. PubMed ID: 10812945 [TBL] [Abstract][Full Text] [Related]
15. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Camps P; Muñoz-Torrero D Mini Rev Med Chem; 2002 Feb; 2(1):11-25. PubMed ID: 12369954 [TBL] [Abstract][Full Text] [Related]
16. Nicotinic treatment of Alzheimer's disease. Newhouse PA; Potter A; Kelton M; Corwin J Biol Psychiatry; 2001 Feb; 49(3):268-78. PubMed ID: 11230878 [No Abstract] [Full Text] [Related]
17. Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. Volpato D; Holzgrabe U Molecules; 2018 Dec; 23(12):. PubMed ID: 30544533 [TBL] [Abstract][Full Text] [Related]
18. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Lombardo S; Maskos U Neuropharmacology; 2015 Sep; 96(Pt B):255-62. PubMed ID: 25514383 [TBL] [Abstract][Full Text] [Related]